¹Ú¿¬Èñ ¸íÀÇ

¾Æ½Ã¾Æ À¯¹æ¾Ï ¿¬±¸¸¦ ¼±µÎÇÏ´Â ±Û·Î¹ú ¸íÀÇ

¹Ú¿¬Èñ ¸íÀÇ

  • ¼Ò ¼Ó
    »ï¼º¼­¿ïº´¿ø
  • Áø·á°ú
    Ç÷¾×Á¾¾ç³»°ú
  • Àü¹®ºÐ¾ß
    À¯¹æ¾Ï

¹Ú¿¬Èñ ±³¼ö´Â ¼¼°èÀûÀÎ À¯¹æ¾Ï ¿¬±¸ÀÇ ¼±±¸ÀÚ·Î ²ÅÈù´Ù. ¹Ú¿¬Èñ ±³¼ö´Â ¼­¾çÀΰú ´Ù¸¥ Çѱ¹ÀÎÀÇ À¯¹æ¾Ï Ư¼º ¿¬±¸¿¡ ½ÉÇ÷À» ±â¿ïÀ̰í ÀÖ´Ù. 2018³â, ¼¼°èÀû ÇмúÁö '³×ÀÌó Ä¿¹Â´ÏÄÉÀ̼ÇÁî'¿¡ Çѱ¹Àο¡°Ô ÈçÇÑ Æó°æ Àü À¯¹æ¾Ï(ÀþÀº À¯¹æ¾Ï) ȯÀÚÀÇ ºÐÀÚ»ý¹°ÇÐÀû Ư¡À» ¹àÈù ³í¹®À» ¹ßÇ¥ÇØ Å« ÁÖ¸ñÀ» ¹Þ¾Ò´Ù. ÀÌ´Â ¼­¾ç°ú ´Þ¸® ¾Æ½Ã¾Æ±Ç ¿©¼º À¯¹æ¾ÏÀÇ Àý¹Ý °¡±îÀ̰¡ Æó°æ Àü¿¡ ¹ß»ýÇÑ´Ù´Â Áß¿äÇÑ Â÷À̸¦ ±Ô¸íÇÑ ¿¬±¸ÀÌ´Ù. ÇöÀçµµ ÀüÀ̼º À¯¹æ¾Ï, Æó°æ Àü À¯¹æ¾Ï µî Çѱ¹ÀΠƯ¼º¿¡ ¸ÂÃá ¿¬±¸¸¦ Áö¼ÓÇϸç, ´Ù¾çÇÑ ±Û·Î¹ú ÀÓ»ó ¿¬±¸ Ã¥ÀÓÀڷΠȰµ¿ ÁßÀÌ´Ù. ÀüÀ̼º À¯¹æ¾Ï ȯÀÚÀÇ »ýÁ¸À² Çâ»óÀ» À§ÇÑ Á¤Ã¥ Á¦¾ð¿¡µµ ¾ÕÀå¼­¸ç, Àü ¼¼°è À¯¹æ¾Ï Ä¡·áÀÇ »õ·Î¿î ±âÁØÀ» ¸¸µé¾î °¡°í ÀÖ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ÀÌÈ­¿©´ë ÀÇ´ë Çлç
  • °æÈñ´ë ÀÇ´ë ¼®»ç
  • °æÈñ´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience

ÇÐȸȰµ¿

Academic activities
  • ´ëÇÑ ¾ÏÇÐȸ Á¤È¸¿ø
  • ´ëÇѳ»°úÇÐȸ Á¤È¸¿ø ¹× ÀÌ»ç
  • ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¤È¸¿ø ¹× ÀÌ»ç
  • ´ëÇÑÇ׾Ͽä¹ý¿¬±¸È¸ Á¤È¸¿ø ¹× À¯¹æ¾Ï ºÐ°úÀå
  • ¹Ì±¹ÀÓ»ó¾ÏÇÐȸ(American Society of Clinical Oncology) Á¤È¸¿ø ¹× IAC À§¿ø
  • À¯·´Á¾¾çÇÐȸ(ESMO) Á¤È¸¿ø
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Whole-genome landscapes of 1,364 breast cancers
¹ßÇ¥³âµµ 2026 ¹ßÇ¥Áö Nature
Á¦ ¸ñ Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö The Lancet Oncology
Á¦ ¸ñ Prevalence of germline BRCA1/2 pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10)
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö The Lancet Regional Health. Western Pacific
Á¦ ¸ñ Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/ pertuzumab for HER2-positive breast cancer
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Breast
Á¦ ¸ñ Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Genome Medicine
Á¦ ¸ñ Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer The Neo-PATH Phase 2 Nonrandomized Clinical Trial
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö JAMA Oncology
Á¦ ¸ñ A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö Clinical Cancer Research

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

»ï¼º¼­¿ïº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1599-3114

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

»ï¼º¼­¿ïº´¿øÀº 1994³â °³¿øÇÑ Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î º»°ü, º°°ü, ¾Ïº´µ¿À¸·Î ±¸¼ºµÅ ÀÖÀ¸¸ç ¾à 1979º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. 2014³â ¾ç¼ºÀÚ Ä¡·á¼¾ÅÍ, 2015³â ¹Ì·¡ ÀÇÇаüÀÌ ¿Ï°øµÆÀ¸¸ç, ÇöÀç 2019³â ¿Ï°øÀ» ¸ñÇ¥·Î Åë¿øÄ¡·á¼¾ÅÍ °ø»ç¸¦ ÁøÇàÇϰí ÀÖ´Ù. ȯÀÚ ÇູÀ» À§ÇÑ ÀÇ·á Çõ½Å ±¸Çö, º´¿ø-¿¬±¸¼Ò-Çб³-±â¾÷ü¸¦ ¿¬°áÇÏ´Â ¹ÙÀÌ¿À ÇコÄÉ¾î ¿¬±¸ ¹× ¿¬°è »ê¾÷ÀÇ ±Û·Î¹ú Çãºê¸¦ ¸ñÇ¥·Î ÇÑ´Ù.

»ï¼º¼­¿ïº´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã °­³²±¸ ÀÏ¿ø·Î 81

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä